HierDTA is a hierarchical structure‑aware framework for drug–target affinity prediction that represents drugs as atom–motif heterogeneous graphs and proteins as residue interaction graphs. It integrates atom and residue representations via cross‑attention, supplemented by molecule fingerprints and pretrained ESM‑2 embeddings, achieving superior performance on the Davis and KIBA datasets and strong generalization in cold‑start scenarios. Ablation studies and interpretability analyses confirm the contributions of its hierarchical augmentation and interaction components, and case studies demonstrate early enrichment of candidate bioactive compounds.
By Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
ProbeMatchDTI is a new framework for drug‑target interaction prediction that uses probe‑driven pattern matching to preserve weak biochemical signals. It introduces IterProbe, which retains contextual states across refinement depths and selects them with learnable probes, and BindingProbe, which models drug‑protein complementarity at both local and whole‑pair levels. Experiments show that ProbeMatchDTI outperforms existing methods, improving AUC‑ROC by 2.0% on BindingDB and 0.5% on DrugBank, and its predictions can be integrated into downstream drug‑discovery workflows.
By Quan Hao, Mengyue Fan, Zifan Dong, Youru Li, Jianduo Zhao, Lechuan Xu, Hao Zhang, Fei Xia, Jigang Wang, Chong Qiu, Liguo Zhang
arXiv:2606. 14159v1 Announce Type: new Abstract: Protein-ligand binding affinity (PLA) prediction is critical in drug discovery.
By Shuai Li, Chuan-Xian Ren, Yuhao Li, Ziqi Huang, Yue Pan, Mingzhe Tang, Hong Yan
arXiv:2608. 09099v1 Announce Type: new Abstract: Quantitative estimation of protein-ligand binding affinity from three-dimensional complex structures is a fundamental task in structure-based computational chemistry and molecular modeling.
By Qingyang Zou, Jiaye Huang, Hangbo Xie, Jiayue Yin, Youyi Song, Jinfeng Liu
arXiv:2609.37384v1 Announce Type: new
Abstract: Molecular representation learning is central to computer-aided drug discovery. Molecular graphs, SMILES strings, and 3D conformations provide complemen...
By Linqing Mo, Jiayu Zhou, Bin Chen
arXiv:2608. 02688v1 Announce Type: cross Abstract: Phenotypic drug discovery enables the discovery of functional relationships between molecular structures and cellular responses.
By Xuan Lin, Jingyu Sheng, Tengfei Ma, Li Sun, Dapeng Xiong
arXiv:2506. 14488v2 Announce Type: replace-cross Abstract: Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution.
By Dong Xu, Zhangfan Yang, Junchuang Cai, Sisi Yuan, Zexuan Zhu, Jianqiang Li, Junkai Ji
ProbeMatchDTI introduces a probe-driven framework for drug‑target interaction prediction that preserves weak biochemical signals by using IterProbe to retain contextual states and BindingProbe to model cross‑entity complementarity at multiple scales. The method improves AUC‑ROC by 2.0% on BindingDB and 0.5% on DrugBank compared to prior biochemical representation learning approaches. Feature‑level analyses confirm the effectiveness of the probe-driven pattern matching, and the predictions are linked to an evidence‑guided downstream drug‑discovery workflow for candidate refinement and validation planning.
The study investigates how different distribution shifts affect the evaluation of drug‑target affinity (DTA) models, using 718,800 drug‑protein pairs from ChEMBL and BindingDB. It compares a baseline Morgan‑fingerprint + protein‑CNN model with 12 architectures that combine four drug representations and three ESM‑2 interaction modes, finding that mean validation RMSE rises significantly under protein‑cluster and dual out‑of‑distribution (OOD) scenarios. Model rankings remain consistent across chemical shifts but diverge under protein and dual OOD, indicating that architecture selection depends on the specific extrapolation context rather than just average error or training‑set size.
Why it matters: The results suggest that DTA benchmarks should be designed to reflect the chemical and target shifts expected in real deployment, ensuring that chosen models perform reliably when applied to new chemical series or protein targets.
By Minjae Chung, Clara Li, Malar Paavai Muthukumaran, Shaunna Wang, Aniket Ramkrishnan Iyer, Shaun Qien Yeau Tan, Harinishree Sathu, Micky C. Nnamdi, J. Ben Tamo, Benoit Louis Marteau, May Dongmei Wang
arXiv:2607. 19237v1 Announce Type: new Abstract: Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeutics.
By Yiming Qin, Kai Yi, Miruna Cretu, Sjors H. W. Scheres, Pietro Li\`o, Pascal Frossard
The paper reports a large-scale, compute-controlled study of Chemical Language Models (CLMs) involving over 30,000 experiments across different molecular representations, tokenizations, model sizes, datasets, and architectures. It finds clear scaling trends in pretraining loss but shows that these improvements do not translate into proportional gains in goal-directed molecular design, with chemical syntax saturating early while semantic properties develop more slowly. The authors release a new suite of models, NovoMolGen, that achieves state-of-the-art results in drug discovery tasks, highlighting a disconnect between representation learning and downstream design and calling for new pretraining paradigms that target chemical semantics.
By Roshan Balaji, Kamran Chitsaz, Quentin Fournier, Nirav Pravinbhai Bhatt, Sarath Chandar
arXiv:2606. 14217v1 Announce Type: new Abstract: Accurate prediction of protein-ligand binding affinity is essential for structure-based drug discovery.
By Peng-Fei Sun, Chuan-Xian Ren, Hong Yan